Introduction South-East Asia accounts for about 45% of the global burden of tuberculosis, and the coalescing of social factors makes the population along the Thai-Myanmar border particularly vulnerable. While a six-months administration of rifampicin-isoniazid-pyrazinamide-ethambutol is a currently available first-line treatment for pulmonary tuberculosis, the impact of some demographic factors and HIV-status on pharmacokinetics and response […]
